CONSERVATIVE TREATMENT OF HEMORRHOIDS. AN ALTERNATIVE TO SURGICAL METHODS OR COMPONENTS? CHORUS PROGRAM RESULTS

OBJECTIVE. Determine the frequency of clinical manifestations of hemorrhoids and constipation in people seeking advice about hemorrhoids. In the course of the treatment of patients with hemorrhoids phlebotropic evaluate the effectiveness of therapy micronized purified flavonoid fraction (MPFF). MATERIALS AND METHODS. This multicenter study, including screening and observation part, which is part of the International Research «CHORUS» (Chronic venous and hemorrhoid diseases evaluation and scientific research), conducted in nine centers in different regions of Russia, 80 doctors of Coloproctology. In the screening group included 2668 patients who had investigated the incidence of constipation, as a risk factor for hemorrhoids. Conservative treatment, the foundation of which was, Moffitt therapy, received 1952 patients with stage I-IV hemorrhoids. Evaluating the effectiveness of the treatment was evaluated on the basis of a questionnaire. RESULTS. The questionnaire shows that constipation suffered - 766 (28,8 %) patients. Violation of defecation patterns and changes in stool consistency was observed in 1155 (43,9%) and 633 (25.5 %), respectively. At the same time, 288 (11,1 %) indicated a tendency to loose stools and diarrhea. Conservative treatment, the foundation of which is phlebotropic MPFF therapy conducted in patients of observational group has shown its efficiency in all grades of hemorrhoids. During the entire observation period of conservative treatment was effective in 1489 (76,3 %) patients. Surgical treatment was performed in 463 (23 %) patients grade I-IV hemorrhoids, the main part of patients with grade III -199 (43,1 %) and grade IV hemorrhoids - 68 (64,2 %). CONCLUSION. Conservative treatment of hemorrhoid disease, which is the basis on phlebotropic MPFF therapy, is effective at all stages of hemorrhoids, but in patients with grade III and grade IV disease requires surgical treatment.

hemorrhoidal disease, anal pain, bleeding, constipation, MPFF

1. Асташов, В.Л. Опыт использования микронизированной очищенной фракции флавоноидов в комплексном лечении геморроидальной болезни. / В.Л.Асташов, Д.А.Тимченко // Колопроктология. -2012. - № 2 (40). - с. 30-33.

2. Благодарный, Л.А. Применение Детралекса в комплексном лечении хронического геморроя 3-4 степени./ Л.А.Благодарный, В.Х.Соттаева // Колопроктология. - 2007. - № 4 (22). - с. 15-17.

3. Благодарный, Л.А. Осложненный геморрой: диагностика и лечение./ Л.А.Благодарный // Стационарозамещающие технологии: Амбулаторная хирургия. - 2015. - № 3-4. - с. 29-34.

4. Воробьев, Г.И. Геморрой. / Г.И.Воробьев, Ю.А.Шелыгин, Л.А.Благодарный // М.: Митра-Пресс, 2002. - 192 с.

5. Маев, И.В. Хронический запор, подходы к постановке диагноза и лечению / И.В.Маев, Е.С.Вьючнова, Е.Г.Лебедева и соавт. // Фарматека. - 2011. - № 12. - с. 58-3.

6. Шелыгин, Ю.А. Справочник по колопроктологии./под ред. Шелыгина Ю.А., Благодарного Л.А. //М.: ГЭОТАР Медиа. - 2012. - 599 с.

7. Шелыгин, Ю.А. Модифицированная классификация геморроя / Ю.А.Шелыгин, А.Ю.Титов, М.В.Абрицова // Колопроктология. - 2015. -№ 2 (52). - с. 4-7.

8. Помазкин, В.И. Влияние «Детралекса» на болевой синдром после геморроидэктомии. / В.И.Помазкин, Ю.В.Мансуров // Колопроктология. - 2009. -№ 2 (28). - с. 1214.

9. Стойко, Ю.М. Патогенетические аспекты консервативной терапии геморроя. / Ю.М.Стойко, Н.Н.Крылов, В.А.Сотникова // Колопроктология. -2006. - № 2 (16). - с. 48-51.

10. Титов, А.Ю. Допплероконтролируемая дезартеризация внутренних геморроидальных узлов с мукопексией и геморроидэктомия (сравнительное, рандомизированное, проспективное исследование) / А.Ю.Титов, М.В.Абрицова //Колопроктология. - 2015. - № 1 (51). - с. 47-48.

11. Alonso-Coello, P. Fiber for the treatment of hemorrhoids complications: a systematic review and metaanalysis./ P.Alonso-Coello, E.Mills, D.Heels-Ansdell et al. // Am. J. Gastroenterol. - 2006. - № 101. - р. 181-88.

12. Aigner, F. The Vascular Nature of Hemorrhoids. / F.Aigner, G.Bodner, H.Gruber et al. // J. Gastrointest. Surg. - 2006. - № 10. - p. 1044-1050.

13. Aigner, F. Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. / F.Aigner, H.Gruber, F.Conrad et al. // Int. J. Colorectal Dis. - 2009. -№ 24. - р. 105-13.

14. Astashov, V. Benefits of micronized purified flavonoid fraction in the reduction of symptoms after operation for hemorrhoidal disease. / V.Astashov, D.Timchenko // Phlebolymphology. - 2014. -№ 21 (2). - p. 95-99.

15. Bharucha, A.E. Functional anorectal disorders. / A.E.Bharucha, A.Wald, P.Enck et al. // Gastroenterology. - 2006. - № 130 (5). - p. 1498-09.

16. Cospite, M. Double-blind, Placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. / M.Cospite //Angiology. - 1994. - № 45. - p. 566-73.

17. Dimitroulopoulos, D. Prospective, Randomized, Controlled, Observer-Blinded Trial of Combined Infrared Photocoagulation and Micronized Purified Flavonoid Fraction Versus each alone for the Treatment of Hemorrhoidal Disease. / D.Dimitroulopoulos, K.Tsamakidis, D.Xinopoulos et al. // Clin. Ther. -2005. - № 27. - p. 746-54.

18. Godeberge, Ph. Daflon 500 mg is significantly more effective than Placebo in the treatment of haemorrhoids. / Ph.Godeberge // Phlebology. - 1992. (Suppl. 2). - p. 61-3.

19. Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. / P.Godeberge // Angiology. - 1994. - № 45. - p. 574-578.

20. Ho, Y.H. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial. / Y.H.Ho, M.Tan, F.Seow-Choen // Dis. Colon Rectum. - 2000. - № 43 (1). - p. 66-9.

21. Ho, Y.H. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. / Y.H.Ho, C.L.Foo, F.Seow-Choen et al. // Br. J. Surg. - 1995. - № 82 (8). - 1034-5.

22. Johanson, J.F. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. / J.F.Johanson, A.Sonnenberg // Gastroenterology. -1990. - № 98. - p. 380-86.

23. Johanson, J.F. Constipation is not a risk factor for hemorrhoids: a case-control study of potential etiological agents. / J.F.Johanson, A.Sonnenberg // Am. J. Gastroenterol. - 1994. - № 89. - p. 1981-86.

24. Korthuis, R.J. Postischemic leukocyte/endothelial cell interaction and microvascular barrier dysfunction in skeletal muscle. Cellular mechanisms and effect of Daflon 500 mg. / R.J.Korthuis, D.C.Gute // Int. J. Microcirc. Clin. Exp. - 1997. - № 17 Suppl 1. - p. 11-7.

25. Labrid, C. Pharmacologic properties of Daflon 500 mg. / C.Labrid // Angiology. - 1994. - № 45. - p. 524-30.

26. Labrid, C. A lymphatic function of Daflon 500 mg. / C.Labrid // Int. Angiol. - 1995. - № 14. - p. 36-38.

27. La Torre, F. Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial. / F.La Torre, A.P.Nicolai // Dis. Colon Rectum. - 2004. - № 47. - p. 704-10.

28. Loder, P.B. Haemorrhoids: pathology, pathophysiology and aetiology. / P.B.Loder, M.A.Kamm, R.J.Nicholls et al. // Br. J. Surg. - 1994. -№ 81. - p. 946-54.

29. Lohsiriwat, V. Approach to hemorrhoids. / V.Lohsiriwat // Curr. Gastroenterol. Rep. - 2013. -№ 15. - p. 332.

30. Lohsiriwat, V. Hemorrhoids: from basic pathophysiology to clinical management. / V.Lohsiriwat // World J.Gastroenterol. - 2012. -№ 18 (17). - p. 2009-17.

31. Longstreth, G.F. Functional Bowel Disorders. / G.F.Longstreth, W.G.Thompson, W.D.Chey et al. // Gastroenterology. - 2006. - № 130 (5). - p. 1480-91.

32. Misra, M.C. Drug treatment of haemorrhoids. / MC.Misra / Drugs. - 2005. - № 65. - p. 1481-91.

33. Moesgaard, F. Highfiber diet reduces bleeding and pain in patients with hemorrhoids: a double-blind trial of Vi-Siblin. / F.Moesgaard, M.L.Nielsen, J.B.Hansen et al. // Dis. Colon Rectum. - 1982. - № 25 (5). -p. 454-6.

34. Morgado, P.J. Histoclinical basis for a new classification of hemorrhoidal disease. / P.J.Morgado, J.A.Suarez, L.G.Gômez et al. // Dis. Colon Rectum. -1988. - № 31. - p. 474-480.

35. Pigot, F. Risk factors associated with hemorrhoidal symptoms in specialized consultation. / F.Pigot, L.Siproudhis, F.A.Allaert // Gastroenterol. Clin. Biol. - 2005. - № 29. - p. 1270-1274.

36. Struckmann, J.R. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. / J.R.Struckmann, A.N. Nicolaides // Angiology. - 1994. - № 45. - p. 419-428.

37. Song Seok-Gyu. Optimal Treatment of Symptomatic Hemorrhoids. / Song Seok-Gyu, Kim Soung-Ho. // J. Korean Soc. Coloproctol. - 2011. -№ 27 (6). - p. 277-81.

38. Thompson, W.G. The road to Rome. / W.G.Thompson // Gastroenterology. - 2006. -№ 130 (5). - p. 1466-79.

39. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. - 2013. - № 310 (20). -p. 2191-94.